Background
Methods
Sex
|
Age at treatment (years)
|
Duration of HC at treatment (years)
|
Phenotype of HC
|
Indomethacin dose required to suppress HC
|
Co-existent headache
|
Previous number of treatments trialled
|
Reasons for administering BoNT-A
|
No of sessions of BoNT-A treatments
|
Average units injected
| |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Location
|
Autonomic symptoms
*
|
Migrainous symptoms
Ŧ
| ||||||||||
1
| M | 19 | 1 | Right | Yes | Nil | 225 mg daily | EMWOA (Bilateral) | 4 | Worsening EM on Indometacin | 4 | 168 |
2
| F | 61 | 1 | Left | Yes | Yes Visual Aura | 150 mg daily | Nil | 4 | GI-upset | 3 | 165 |
3
| M | 59 | 12 | Right | Yes | Nil | IM Indometacin test** | Nil | 13 | Unable tolerate Indometacin; Refractory to other treatments; ONS in-situ | 2 | 175 |
4
| M | 48 | 2 | Right | Yes | Yes Visual Aura (occasional) | 150 mg daily | EMWA (bilateral, once month) | 9 | GI-upset; peptic ulcer disease; refractory to other treatments - awaiting ONS | 2 | 165 |
5
| F | 47 | 9 | Right | Yes | Yes | 225 mg daily | Past EMWOA (stopped 2004) | 3 | GI-upset | 5 | 167 |
6
| F | 49 | 34 | Right | Yes | Yes | 150 mg daily | EMWA (bilateral, once month) | 6 | GI-upset; refractory to other treatments; ONS in-situ | 2 | 110 |
7
| F | 48 | 18 | Left | Yes | Yes | IM Indometacin test** | ISH | 13 | GI-upset | 2 | 155 |
8
| F | 41 | 8 | Right | Yes | No Visual Aura | 150 mg daily | EMWOA (side variable/bilateral) | 7 | GI-upset; wheeze; dizziness; worsening EM | 6 | 168 |
9
| F | 54 | 4 | Right | Yes | Yes | 225 mg daily | Nil | 9 | GI-upset | 2 | 185 |
Mean
|
47
|
10
|
8
|
3
|
162
| |||||||
Median (Range)
|
48 (19–61)
|
8 (1–34)
|
7 (3-13)
|
2 (2-6)
|
167 (110–185)
|
Results
ID
|
Average headache days/month
|
Average moderate -severe days/month*
|
Average daily headache hours
|
Average daily VRS
|
Change in headache load (%)
|
Subjective estimate of response
|
Estimated duration of response (weeks)
| ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre
|
Post
|
Change %
|
Pre
|
Post
|
Change %
|
Pre
|
Post
|
Change %
|
Pre
|
Post
|
Change %
| ||||
1
| 30 | 0 | 100 | 20 | 0 | 100 | 24 | 0 | 100 | 5 | 0 | 100 | 100 | >90% | 16 |
2
| 30 | 0 | 100 | 15 | 0 | 100 | 24 | 0 | 100 | 5 | 0 | 100 | 100 | >90% | 20 |
3
| 30 | 30 | 0 | 30 | 19 | 37 | 24 | 24 | 0 | 8 | 6 | 25 | 20 | 30-50% | 5 |
4
| 30 | 30 | 0 | 30 | 30 | 0 | 24 | 24 | 0 | 7 | 6 | 14 | 0 | 0 | 0 |
5
| 30 | 3 | 90 | 30 | 3 | 90 | 24 | 6 | 75 | 7 | 10 | 0 | 98 | 80-90% | 12 |
6
| 30 | 30 | 0 | 30 | 23 | 23 | 15 | 16 | 0 | 7 | 6 | 14 | 0 | 15-25% | 4 |
7
| 30 | 22 | 27 | 21 | 13 | 27 | 24 | 7 | 71 | 7 | 4 | 43 | 55 | 40% | 6 |
8
| 30 | 2 | 93 | 30 | 0 | 100 | 24 | 8 | 67 | 9 | 2 | 78 | 99 | 80-90% | 6 |
9
| 30 | 0 | 100 | 30 | 0 | 100 | 24 | 0 | 100 | 8 | 0 | 100 | 100 | >90% | 9 |
Mean
|
30
|
13
|
57
|
25
|
10
|
64
|
23
|
9
|
57
|
7
|
4
|
51
|
62
|
8
| |
Median (Range)
|
30 (30)
|
3 (0–30)
|
90 (0–100)
|
30 (15–30)
|
3 (0–30)
|
80 (0–100)
|
24 (15–24)
|
7 (0–24)
|
71 (0–100)
|
7 (5-9)
|
4 (0–10)
|
43 (0–100)
|
98 (0–100)
|
6 (0–20)
|
ID
|
HIT-6
|
MIDAS
|
HAD-A
|
HAD-D
| ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre
|
Post
|
Change in score
|
Pre
|
Post
|
Change in score
|
Pre
|
Post
|
Change in score
|
Pre
|
Post
|
Change in score
| |
1
| 65 | 58 | 7 | 73 | 0 | 73 | 10 | 8 | 2 | 9 | 3 | 6 |
2
| 57 | 36 | 21 | 24 | 0 | 24 | 1 | 0 | 1 | 0 | 0 | 0 |
3
| 56 | 68 | −12 | 52 | 52 | 0 | 3 | 9 | −6 | 2 | 12 | −10 |
4
| 68 | 67 | 1 | 105 | 130 | −25 | 12 | 6 | 6 | 10 | 8 | 2 |
5
| 67 | 44 | 23 | 120 | 0 | 120 | 9 | 2 | 7 | 9 | 1 | 8 |
6
| 63 | 60 | 3 | 121 | 13 | 108 | 16 | 18 | −2 | 15 | 15 | 0 |
7
| 63 | 54 | 9 | 24 | 13 | 9 | 2 | 3 | −1 | 5 | 7 | −2 |
8
| 64 | 62 | 2 | 240 | 4 | 236 | 0 | 0 | 0 | 3 | 0 | 3 |
9
| 76 | 24 | 52 | 51 | 0 | 51 | 12 | 0 | 12 | 4 | 0 | 4 |
Mean
|
64
|
53
|
12
|
90
|
24
|
66
|
7
|
5
|
2
|
6
|
5
|
1
|
Median (Range)
|
64 (56–76)
|
58 (24–68)
|
7 (−12 to 52)
|
73 (24–240)
|
4 (0–130)
|
51 (−25 to 236)
|
9 (0–16)
|
3 (0–18)
|
1 (−6 to 12)
|
5 (0–15)
|
3 (0–15)
|
2 (−10 to 8)
|